Targeting the booming billion-dollar pet care market, MountainVet Biotech and Protect Animal Health announced a strategic alliance on the 16th. The two companies will integrate their strengths in R&D, clinical practice, and market channels to build a comprehensive veterinary healthcare system that spans prevention, diagnosis, treatment, and regenerative care, jointly accelerating expansion into the Asia-Pacific and global markets.
MountainVet Biotech is a leading brand in Taiwan specializing in animal disease diagnostics and senior pet care, with a vast network of nearly 1,000 partner veterinary clinics and expertise in stem cell and regenerative medicine. Protect Animal Health, on the other hand, focuses on the development of innovative pharmaceuticals for pets.
Huang, Chang-Fu, General Manager of MountainVet Biotech, stated that the alliance with Protect Animal Health will not only bring stronger resources in innovative drug development but will also allow MountainVet to incorporate its frontline clinical insights, diagnostic practices, and market operations into the pharmaceutical development process—creating a new innovation model that is more closely aligned with market needs.
With over a decade of experience in Taiwan’s veterinary healthcare network, MountainVet has built long-term partnerships with nearly a thousand animal hospitals, offering key technical support in molecular diagnostics, PCR testing, and genetic disease screening, making it a vital partner in veterinary clinical diagnostics. In recent years, the company has also actively promoted regenerative medicine applications for pets. It is the first biotech company in Taiwan to venture into the field of exosome technology, collaborating with Syncell Biotech to integrate AI with exosome preparation and offer personalized regenerative therapies tailored to pets.
Huang emphasized that MountainVet has accumulated a substantial amount of diagnostic data and application experience from the frontlines of the market. This partnership with Protect Animal Health will enhance the drug development-to-market validation process and accelerate the translation of therapies—meeting the growing demand from pet owners and veterinarians for effective and precise care.
Protect Animal Health is a pioneering company in Taiwan's innovative pet drug development sector and has received investment from several well-known firms, including EirGenix, RengenBio, Panion & BF Biotech, EverGlory Biotech, and CTBC Venture Capital—highlighting its growth potential in the global pet healthcare market.
Chairman Haolin Sung remarked that this collaboration marks a major milestone in resource integration between the two companies. By combining Protect Animal Health’s strengths in new drug development and international resources with MountainVet’s robust foundation in diagnostic technology, clinical validation, and veterinary channels, the alliance will significantly enhance the implementation and outcomes of innovative therapies. MountainVet will also serve as a crucial bridge for Protect Animal Health’s pharmaceutical products to enter the market, supporting evidence-based validation and full-channel deployment.
Resource: 瞄準千億毛孩商機 牧騰、寶泰策略結盟
